Perspectives on personalized radiopharmaceutical dosimetry from the YSOTOPE team. Covering PK modeling, molecular imaging protocols, clinical workflow, and the science behind patient-specific theranostics.
Building a two-compartment PK model for each patient used to require manual parameter fitting that few clinics could afford. Here is how we automated that process without sacrificing physiological accuracy.
Accurate PSMA PET-derived SUV quantification is the upstream dependency for everything downstream in personalized lutetium-PSMA dosing. This post walks through acquisition protocols that preserve quantitative accuracy.
Body weight, renal clearance, and tumor receptor density vary independently. Fixed-activity protocols cannot account for all three simultaneously. This post quantifies what that variability means for absorbed dose windows.
Iodine-124 PET allows true dosimetry-driven activity calculation for differentiated thyroid cancer patients before radioiodine ablation. We compare scan-guided vs. empiric approaches across a range of patient profiles.
Administered activity in megabecquerels and absorbed dose in gray measure different things. Understanding that difference is essential for reading dosimetry reports and translating them into clinical decisions.
Quantitative imaging pipelines, organ segmentation, PK fitting engines, and dose reporting need to connect without breaking clinical workflow. We describe the architectural decisions behind the YSOTOPE platform.
Neuroendocrine tumor patients have highly variable somatostatin receptor expression between lesions. Cycle-by-cycle dosimetry using quantitative SPECT is the only way to track inter-lesion heterogeneity across treatment.
Quantitative SPECT reconstruction is no longer a research tool. Most modern gamma cameras support it natively. This post covers the practical steps to enable attenuation-corrected quantitative SPECT in a standard department.
Renal toxicity is the primary dose-limiting factor for lutetium-based therapies. Accurate kidney dosimetry from serial SPECT imaging is essential to avoid overexposure while delivering therapeutic tumor doses.
Six months into our early-access pilot program with three oncology centers, we share what the dose modeling data revealed about inter-patient variability and where our algorithms performed better than expected.
When tumor uptake, clearance half-life, and organ sensitivity vary independently across patients, the population-mean dose hits very few patients in the therapeutic window. We model that variance and its clinical implications.
